Ibritumomab tiuxetan
- Generic Name
- Ibritumomab tiuxetan
- Brand Names
- Zevalin
- Drug Type
- Biotech
- CAS Number
- 206181-63-7
- Unique Ingredient Identifier
- 4Q52C550XK
- Background
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
- Indication
For treatment of non-Hodgkin's lymphoma
- Associated Conditions
- Follicular Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma Refractory, Relapsed follicular B-cell non-Hodgkin's lymphoma
WuXi AppTec Predicts Shift from Antibodies to Peptides in Radiopharmaceutical Development
• WuXi AppTec's VP Dr. Dave Madge highlights potential transition from antibody-based to peptide-based radiotherapeutics, citing advantages in tissue penetration and reduced toxicity.
• Major pharmaceutical companies including Bristol Myers Squibb, Novartis, and Eli Lilly have made significant investments in radiopharmaceuticals, with deals ranging from $1.4B to $4.2B.
• WuXi AppTec expands peptide manufacturing capacity with two new facilities in China, responding to growing global demand despite potential challenges from US BIOSECURE Act.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath